AFT Pharmaceuticals Limited (NZE:AFT)

New Zealand flag New Zealand · Delayed Price · Currency is NZD
3.500
-0.020 (-0.57%)
At close: Mar 2, 2026
29.63%
Market Cap 367.03M
Revenue (ttm) 236.25M
Net Income (ttm) 17.45M
Shares Out 104.87M
EPS (ttm) 0.16
PE Ratio 21.63
Forward PE 23.42
Dividend 0.02 (0.51%)
Ex-Dividend Date Jun 18, 2025
Volume 7,994
Average Volume 7,802
Open 3.520
Previous Close 3.520
Day's Range 3.500 - 3.520
52-Week Range 2.410 - 3.800
Beta 0.43
RSI 40.35
Earnings Date Feb 18, 2026

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta... [Read more]

Sector Healthcare
Founded 1997
Employees 119
Stock Exchange New Zealand Stock Exchange
Ticker Symbol AFT
Full Company Profile

Financial Performance

In fiscal year 2025, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.

Financial Statements

News

AFT Pharmaceuticals Ltd (ASX:AFP) Half Year 2026 Earnings Call Highlights: Strong Sales Growth ...

AFT Pharmaceuticals Ltd (ASX:AFP) Half Year 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Expansion

3 months ago - GuruFocus

Half Year 2026 AFT Pharmaceuticals Ltd Earnings Call Transcript

Half Year 2026 AFT Pharmaceuticals Ltd Earnings Call Transcript

3 months ago - GuruFocus